Anaptysbio (ANAB) Operating Expenses (2016 - 2026)

Anaptysbio's Operating Expenses history runs 11 years deep, the most recent figure standing at $60.2 million for Q1 2026.

• Quarterly Operating Expenses rose 8.83% year-over-year to $60.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $191.6 million (down 9.7% YoY) and the FY2025 annual result came in at $186.7 million, down 9.47% from the prior year.
• Operating Expenses was $60.2 million for Q1 2026 at Anaptysbio, up from $41.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $60.2 million in Q1 2026 and bottomed at $29.0 million in Q2 2022.
• A 5-year average of $44.7 million and a median of $45.8 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2023 — Operating Expenses soared 56.01% — and 2025, when it declined 21.66%.
• Anaptysbio's Operating Expenses stood at $32.8 million in 2022, then surged by 56.01% to $51.1 million in 2023, then advanced by 3.21% to $52.8 million in 2024, then declined by 21.66% to $41.3 million in 2025, then soared by 45.58% to $60.2 million in 2026.
• Business Quant data shows ANAB's Operating Expenses at $60.2 million in Q1 2026, $41.3 million in Q4 2025, and $41.6 million in Q3 2025.